血清调节性T细胞比率、白细胞介素-17、白细胞介素-34与晚期肾癌免疫治疗疗效的关系  

Relationship between serum regulatory T cell ratio,interleukin-17,interleukin-34 and immunotherapy efficacy of advanced renal carcinoma

作　　者：朱慧兰 郭叶 ZHU Huilan;GUO Ye(Department of Nephrology,Beijing Pinggu Hospital,Beijing 101299,China;Department of Oncology,Peking University International Hospital,Beijing 102206,China)

机构地区：[1]北京市平谷区医院肾内科,北京101299 [2]北京大学国际医院肿瘤科,北京102206

出　　处：《癌症进展》2025年第1期47-50,共4页Oncology Progress

基　　金：北京市平谷区医院青年人才科研项目(Pgyyqn2021-03)。

摘　　要：目的探讨血清调节性T细胞(Treg)比率、白细胞介素-17(IL-17)、白细胞介素-34(IL-34)与晚期肾癌免疫治疗疗效的关系。方法将60例晚期肾癌患者按照免疫治疗疗效情况分为有效控制组(n=39)和无效死亡组(n=21)。比较两组患者免疫治疗前血清Treg比率、IL-17、IL-34水平,采用多因素Cox回归分析评估血清Treg比率、IL-17、IL-34水平与免疫治疗疗效的关系。采用受试者工作特征(ROC)曲线分析血清Treg比率、IL-17、IL-34水平对晚期肾癌患者免疫治疗疗效的预测价值。结果无效死亡组患者血清Treg比率、IL-17、IL-34水平均明显高于有效控制组,差异均有统计学意义(P﹤0.01)。多因素Cox回归分析结果显示,血清Treg比率、IL-17、IL-34水平升高均为晚期肾癌患者免疫治疗疗效的危险因素(P﹤0.05)。ROC曲线中,血清Treg比率、IL-17、IL-34水平预测晚期肾癌患者免疫治疗疗效的曲线下面积(AUC)分别为0.835、0.761、0.792,灵敏度分别为100%、66.67%、71.43%,特异度分别为71.79%、74.36%、94.87%。结论血清Treg比率、IL-17、IL-34水平与晚期肾癌患者免疫治疗疗效密切相关,监测晚期肾癌患者血清Treg比率、IL-17、IL-34水平有利于预测其免疫治疗疗效,为临床免疫治疗靶点的选择提供参考依据。Objective To investigate the relationship between serum regulatory T cell(Treg)ratio,interleukin-17(IL-17),interleukin-34(IL-34)and immunotherapy efficacy of advanced renal carcinoma.Method A total of 60 patients with advanced renal carcinoma were divided into effective control group(n=39)and ineffective death group(n=21)according to the efficacy of immunotherapy.Serum Treg ratio,IL-17 and IL-34 levels before immunotherapy were compared between the two groups,and the relationship between serum Treg ratio,IL-17,IL-34 levels and immunotherapy efficacy were evaluated by multivariate Cox regression analysis.The predictive value of serum Treg ratio,IL-17 and IL-34 levels for immunotherapy efficacy in patients with advanced renal carcinoma were analyzed by receiver operating characteristic(ROC)curve.Result The serum Treg ratio,the levels of IL-17 and IL-34 in the ineffective death group were significantly higher than those in the effective control group,the differences were statistically significant(P<0.01).Multivariate Cox regression analysis showed that the increase of serum Treg ratio,IL-17 and IL-34 levels were risk factors for immunotherapy efficacy in advanced renal carcinoma patients(P<0.05).In ROC curve,the area under the curve(AUC)of serum Treg ratio,IL-17 and IL-34 levels to predict the efficacy of immunotherapy in patients with advanced renal carcinoma were 0.835,0.761 and 0.792,respectively,and the sensitivity were 100%,66.67% and 71.43%,respectively,the specificity were 71.79%,74.36% and 94.87%,respectively.Conclusion Serum Treg ratio,IL-17 and IL-34 levels are closely related to the efficacy of immunotherapy in patients with advanced renal carcinoma.Monitoring serum Treg ratio,IL-17 and IL-34 levels in patients with advanced renal carcinoma is conducive to predicting the efficacy of immunotherapy and providing reference for the selection of clinical immunotherapy targets.

关 键 词：调节性T细胞比率 白细胞介素-17 白细胞介素-34 晚期肾癌 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]